1. McKhann G, Drachman D, Folsn M, Katzman R, Price D, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939-44.

2. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:270-79.

3. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Assocation workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:280-92.

4. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 2011;7:263-69.

5. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 2014;13:614-29.

6. Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 2019;142:1503-27.

7. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018;14:535-62.

8. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H. Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. Biomark Med 2012;6:419-30.

9. Paraskevas GP, Kaselimis D, Kourtidou E, Constantinides V, Bougea A, et al. Cerebrospinal fluid biomarkers as a diagnostic tool of the underlying pathology of primary progressive aphasia. J Alzheimers Dis 2017;55:1453-61.

10. Bourbouli M, Kapaki E, Petropoulou O, Paraskevas GP. Improved performance of CSF dementia biomarker measurements over time: the effect of quality control and harmonization programs. Biomark Applic 2018; doi: 10.29011/BMAP-126.100026.

11. Kapaki E, Paraskevas GP, Zalonis I, Zournas C. CSF tau protein and beta-amyloid (1-42) in Alzheimer’s disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. Eur J Neurol 2003;10:119-28.

12. Folstein M, Folstein S, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.

13. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology 2000;55:1621-26.

14. Jack CR Jr. PART and SNAP. Acta Neuropathol 2014;128:773-6.

15. Simonsen AH, Herukka SK, Andreasen N, Baldeiras I, Bjerke M, et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer’s Dement 2017;13:274-84.

16. Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J. Amyloid b 42/40 CSF concentration ratio in the diagnostics of Alzheimer’s Disease: validation of two novel assays. J Alzheimer’s Dis 2015;43:183-91.

17. Blennow K, Zetterberg H. The past and the future of Alzheimer’s disease fluid biomarkers. J Alzheimers Dis 2018;62:1125-40.

18. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456-77.

19. Lleó A, Irwin DJ, Illán-Gala I, McMillan CT, Wolk DA, et al. A 2-Step cerebrospinal algorithm for the selection of frontotemporal lobar degeneration subtypes. JAMA Neurol 2018;75:738-45.

20. Wallin A, Nordlund A, Jonsson M, Blennow K, Zetterberg H, et al. Alzheimer’s disease-subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies. J Cereb Blood Flow Metab 2016;36:95-113.

21. Paraskevas GP, Kapaki E, Papageorgiou SG, Kalfakis N, Andreadou E, et al. CSF biomarker profile and diagnostic value in vascular dementia. Eur J Neurol 2009;16:205-11.

22. Paraskevas GP, Constantinides VC, Pyrgelis ES, Kapaki E. Mixed Small Vessel Disease in a Patient with Dementia with Lewy Bodies. Brain Sci 2019;9:pii: E159.

23. Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer’s disease. Neuron 2013;80:1347-58.

24. Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 2011;122:137-53.

25. Dong Y, Chen Y. The role of ubiquitinated TDP-43 in amyotrophic lateral sclerosis. Neuroimmunol Neuroinflammation 2018;5:5.

26. McCleery J, Flicker L, Richard E, Quinn TJ. When is Alzheimer’s not dementia-Cochrane commentary on the national institute on ageing and Alzheimer’s association research framework for Alzheimer’s disease. Age Ageing 2019;48:174-7.

27. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 2017;89:88-100.

28. Skogseth R, Hortobágyi T, Soennesyn H, Chwiszczuk L, Ffytche D, et al. Accuracy of clinical diagnosis of dementia with lewy bodies versus neuropathology. J Alzheimer’s Dis 2017;59:1139-52.

29. Paraskevas GP, Bougea A, Constantinides VC, Bourbouli M, Petropoulou O, et al. In vivo prevalence of alzheimer biomarkers in dementia with lewy bodies. Dement Geriatr Cogn Disord 2019;47:289-96.

30. Formichi P, Parnetti L, Radi E, Cevenini G, Dotti MT, et al. CSF biomarkers profile in CADASIL-a model of pure vascular dementia: usefulness in differential diagnosis in the dementia disorder. Int J Alzheimers Dis 2010;2010:959257.

31. Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease. Nat Commun 2020;11:1683.

32. Bourbouli M, Rentzos M, Bougea A, Zouvelou V, Constantinides VC, et al. Cerebrospinal fluid TAR DNA-binding protein 43 combined with tau proteins as a candidate biomarker for amyotrophic lateral sclerosis and frontotemporal dementia spectrum disorders. Dement Geriatr Cogn Disord 2017;44:144-52.

33. Paraskevas GP, Bourbouli M, Zaganas I, Kapaki E. The emerging TDP-43 proteinopathy. Neuroimmunol Neuroinflammation 2018;5:17.

34. Kapaki E, Paraskevas GP, Emmanouilidou E, Vekrellis K. The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer’s disease. PLoS One 2013;8:e81654.

35. Bougea A, Stefanis L, Paraskevas GP, Emmanouilidou E, Efthymiopoulou E, et al. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson’s disease dementia, dementia with Lewy bodies and Alzheimer’s disease. J Neurol 2018;265:2295-301.

36. Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med 2020;26:379-86.

37. Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 2019;93:e1647-59.

38. Wallin A, Kapaki E, Boban M, Engelborghs S, Hermann DM, et al. Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report. BMC Neurol 2017;17:102.

39. Rentzos M, Paraskevas GP, Kapaki E, Nikolaou C, Zoga M, et al. Circulating interleukin-15 in dementia disorders. J Neuropsychiatry Clin Neurosci 2007;19:318-25.

40. Rentzos M, Zoga M, Paraskevas GP, Kapaki E, Rombos A, et al. IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer’s disease and frontotemporal dementia. J Geriatr Psychiatry Neurol 2006;19:114-7.

41. Rentzos M, Paraskevas GP, Kapaki E, Nikolaou C, Zoga M, et al. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer’s disease and frontotemporal dementia. J Neurol Sci 2006;249:110-4.

Neuroimmunology and Neuroinflammation
ISSN 2349-6142 (Online) 2347-8659 (Print)


All published articles are preserved here permanently:


All published articles are preserved here permanently: